[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337403-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337403-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","apobec-mutagenesis-in-cancer-development-and-susceptibility","APOBEC Mutagenesis in Cancer Development and Susceptibility","","APOBEC cytosine deaminases act as major mutators across human cancers, driving mutations in more than half of cases. Their mutagenesis is associated with tumor heterogeneity, ongoing cellular evolution, and distinct therapy responses, yet its role in cancer susceptibility and malignant transformation remains incompletely defined. The review evaluates reported links from germline polymorphisms in APOBEC-enzyme genes, sequencing-based insights from malignant and non-malignant tissues, and in vivo evidence, then outlines key knowledge gaps and future directions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/apobec-mutagenesis-in-cancer-development-and-susceptibility/337403/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/apobec-mutagenesis-in-cancer-development-and-susceptibility/337403.png","ImageObject",300,407,{"name":42,"@type":43},"Logic","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are APOBEC cytosine deaminases and why are they important in cancer?","Question",{"text":63,"@type":64},"APOBEC cytosine deaminases are prominent mutators in cancer. They mediate mutations in over 50% of cancers and are linked to tumor heterogeneity and therapy responses.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does APOBEC mutagenesis relate to cancer progression?",{"text":68,"@type":64},"Emerging evidence supports that APOBEC mutagenesis impacts cancer progression. It is associated with persistent cell evolution and therapy responses, although the contribution to susceptibility and malignant transformation is still limited.",{"name":70,"@type":61,"acceptedAnswer":71},"What types of evidence does the review use to study APOBEC mutagenesis?",{"text":72,"@type":64},"The review examines germline polymorphisms in APOBEC-enzyme genes and evaluates APOBEC activities using sequencing of malignant and non-malignant human tissues, complemented by in vivo studies. It also discusses key knowledge gaps and directions for deeper understanding.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337403,1790219739,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","cancers   \nCommentary  \nAPOBEC Mutagenesis in Cancer Development and Susceptibility  \nAlexandra Dananberg 1, Josefine Striepen 1, Jacob S. Rozowsky 2,3 and Mia Petljak 3,4, *  \nCitation: Dananberg, A.; Striepen, J.; Rozowsky, J.S.; Petljak, M. APOBECMutagenesis in Cancer Development and Susceptibility. Cancers 2024, 16, 374. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers16020374  \nAcademic Editor: Youri I. Pavlov  \nReceived: 20 December 2023  \nRevised: 9 January 2024  \nAccepted: 11 January 2024  \nPublished: 15 January 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Molecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; [ald2042@med.cornell.edu](ald2042@med.cornell.edu) (A.D.); [jus4013@med.cornell.edu](jus4013@med.cornell.edu) (J.S.)  \n2 Medical Scientist Training Program, New York University Grossman School of Medicine, New York, NY 10016, USA; [jacob.rozowsky@nyulangone.org](jacob.rozowsky@nyulangone.org)  \n3 Department of Pathology, NYU Grossman School of Medicine, New York, NY 10016, USA  \n4 Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY 10016, USA  \n* [Correspondence: mia.petljak@nyulangone.org](Correspondence: mia.petljak@nyulangone.org)  \nSimple Summary: APOBEC cytosine deaminases represent potent mutational sources in over 50% of human cancers and are linked to tumor heterogeneity and therapy responses. However, the understanding of the contribution of APOBEC-mediated mutagenesis to cancer susceptibility and malignant transformation is still limited. The authors review the existing evidence for the impact of APOBEC mutagenesis on cancer development and identify gaps in related knowledge that need tobe addressed.  \nAbstract: APOBEC cytosine deaminases are prominent mutators in cancer, mediating mutations in over 50% of cancers. APOBEC mutagenesis has been linked to tumor heterogeneity, persistent cell evolution, and therapy responses. While emerging evidence supports the impact of APOBECmutagenesis on cancer progression, the understanding of its contribution to cancer susceptibility and malignant transformation is limited. We examine the existing evidence for the role of APOBECmutagenesis in carcinogenesis on the basis of the reported associations between germline polymorphisms in genes encoding APOBEC enzymes and cancer risk, insights into APOBEC activities from sequencing efforts of both malignant and non-malignant human tissues, and in vivo studies. We discuss key knowledge gaps and highlight possible ways to gain a deeper understanding of the contribution of APOBEC mutagenesis to cancer development.  \nKeywords: APOBEC deaminases; APOBECmutagenesis; cancer; carcinogenesis; cancer susceptibility; cancer development; APOBEC mutational signatures  \n1. Introduction  \nThe AID (activation-induced cytidine deaminase)/APOBEC (apolipoprotein B mRNA editing enzyme catalytic subunit) family comprises eleven members as follows: AID, APOBEC1, APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D/E, APOBEC3F, APOBEC3G, APOBEC3H, and APOBEC4 . While APOBEC2 and APOBEC4 members lack known deaminase activities, other enzymes play pivotal roles in immune and metabolic processes [1–7] . Put briefly, AID-mediated cytosine deamination at immunoglobulin loci contributes to somatic hypermutation and antibody diversification; APOBEC1-mediated cytidine deamination generates a lower molecular weight form of apolipoprotein B (ApoB) in the small intestine, which is essential for triglyceride transport; and the APOBEC3 subfamily-mediated deamination of retroviral and viral cytosines and cytidines limits vira","cbCaialdK1eQ5By3","https://ap.wps.com/l/cbCaialdK1eQ5By3","pdf",2441834,15,"English","# 1. Introduction\n## AID/APOBEC family and biological roles\n## APOBEC enzymes as prominent cancer mutators\n## APOBEC-associated mutational signatures in cancer genomes\n## AID-linked mutations in cancer genomes","[{\"question\":\"What are APOBEC cytosine deaminases and why are they important in cancer?\",\"answer\":\"APOBEC cytosine deaminases are prominent mutators in cancer. They mediate mutations in over 50% of cancers and are linked to tumor heterogeneity and therapy responses.\"},{\"question\":\"How does APOBEC mutagenesis relate to cancer progression?\",\"answer\":\"Emerging evidence supports that APOBEC mutagenesis impacts cancer progression. It is associated with persistent cell evolution and therapy responses, although the contribution to susceptibility and malignant transformation is still limited.\"},{\"question\":\"What types of evidence does the review use to study APOBEC mutagenesis?\",\"answer\":\"The review examines germline polymorphisms in APOBEC-enzyme genes and evaluates APOBEC activities using sequencing of malignant and non-malignant human tissues, complemented by in vivo studies. It also discusses key knowledge gaps and directions for deeper understanding.\"}]","APOBEC Mutagenesis in Cancer Development and Susceptibility | PDF",1790018988,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e48c83c9858d9bab7b66211b71e35996.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7509d073d1de8c12bd1b6062a4e14a0b.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6770e96a6ea7f0653b53666e2333d1cf.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e749c945845b089ffbb7e13f8ced0939.webp",980,1385]